TENX · Tenax Therapeutics Inc

-

Please sign in to comment on TENX

1 Comment

Admin

4 years, 1 month ago

Tenax Therapeutics, Inc is currently in a long term uptrend where the price is trading 10.8% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Tenax Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 1.4% to $-3M since the same quarter in the previous year.

Finally, its free cash flow fell by 15.1% to $-2M since the same quarter in the previous year.

Based on the above factors, Tenax Therapeutics, Inc gets an overall score of 2/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	NASDAQ
CurrencyCode	USD
ISIN	US88032L2097

Target Price	17.2
Market Cap	24M
PE Ratio	None
Beta	1.91
Dividend Yield	None

ABOUT

Tenax Therapeutics Inc

Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

TENX · Tenax Therapeutics Inc

-

Tenax Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Tenax Therapeutics Inc using a moving average strategy